November 12, 2020
Fundación MEDINA collaborates with its metabolomics platform in the DE R&D project on liquid biopsy in prostate cancer, led by the Recoletas Campo Grande Hospital, in alliance with IBSAL (Biomedical Research Institute of Salamanca) and Atrys Health, through which to develop a molecular signature to predict the response to radiotherapy treatments and the early detection of relapses.
The RADIOPROLIQ Project, with a budget of more than one million euros, has the support of the Ministry of Science and Innovation through the call for R+D+i Projects "Retos-Colaboración" of the State Program for Research, Development and Innovation Oriented to the Challenges of Society.
Fundación MEDINA has a bioanalytical platform based on mass spectrometry that has also made it possible to handle several projects focused on the discovery of new biomarkers for different pathophysiological situations. MEDINA leads a state-of-the-art automated high resolution analytical platform that allows the evaluation of biomolecules and the identification of new metabolomic biomarkers from a wide range of biological samples. MEDINA contributes to clinical and translational research in the development of toxicological and pharmacological studies in the early stages of development of new drugs, as well as in the identification of alterations in the complex patterns of the metabolic profile of patients.
